Literature DB >> 12620195

The c-Myc Oncoprotein Interacts with Bcr.

Gwendolyn M Mahon1, Yan Wang, Malgorzata Korus, Elena Kostenko, Li Cheng, Tong Sun, Ralph B Arlinghaus, Ian P Whitehead.   

Abstract

Bcr is a multifunctional protein that is the fusion partner for Abl (p210 Bcr-Abl) in Philadelphia chromosome positive leukemias. We have identified c-Myc as a binding partner for Bcr in both yeast and mammalian cells. We are also able to observe interactions between natively expressed c-Myc and Bcr in leukemic cell lines. Although Bcr and Max have overlapping binding sites on c-Myc, Bcr cannot interact with Max, or with the c-Myc.Max heterodimer. Bcr expression blocks activation of c-Myc-responsive genes, as well as the transformed phenotype induced by coexpression of c-Myc and H-Ras, and this finding suggests that one function of Bcr is to limit the activity of c-Myc. However, Bcr does not block c-Myc function by preventing its nuclear localization. Interestingly, increased Bcr dosage in COS-7 and K-562 cells correlates with a reduction in c-Myc protein levels, suggesting that Bcr may in fact be limiting c-Myc activity by regulating its stability. These data indicate that Bcr is a novel regulator of c-Myc function whose disrupted expression may contribute to the high level of c-Myc protein that is observed in Bcr-Abl transformed cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620195     DOI: 10.1016/s0960-9822(03)00090-3

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  9 in total

1.  Bcr is a negative regulator of the Wnt signalling pathway.

Authors:  Angelika Ress; Karin Moelling
Journal:  EMBO Rep       Date:  2005-10-07       Impact factor: 8.807

2.  Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.

Authors:  Ru Chen; Tinghui Hu; Gwendolyn M Mahon; Ilona Tala; Nicole L Pannucci; Harvey L Ozer; Ian P Whitehead
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

3.  Ccpg1, a novel scaffold protein that regulates the activity of the Rho guanine nucleotide exchange factor Dbs.

Authors:  Elena V Kostenko; Oyenike O Olabisi; Sutapa Sahay; Pedro L Rodriguez; Ian P Whitehead
Journal:  Mol Cell Biol       Date:  2006-09-25       Impact factor: 4.272

4.  The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Authors:  S Sahay; N L Pannucci; G M Mahon; P L Rodriguez; N J Megjugorac; E V Kostenko; H L Ozer; I P Whitehead
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

5.  Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.

Authors:  B Perazzona; H Lin; T Sun; Y Wang; R Arlinghaus
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

6.  BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility.

Authors:  Xiaomin Zheng; Saskia Güller; Tim Beissert; Elena Puccetti; Martin Ruthardt
Journal:  BMC Cancer       Date:  2006-11-07       Impact factor: 4.430

7.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

8.  Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.

Authors:  N L Pannucci; D Li; S Sahay; E K Thomas; R Chen; I Tala; T Hu; B T Ciccarelli; N J Megjugorac; H C Adams Iii; P L Rodriguez; E R Fitzpatrick; D Lagunoff; D A Williams; I P Whitehead
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

Review 9.  Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.

Authors:  M Beloueche-Babari; Y-L Chung; N M S Al-Saffar; M Falck-Miniotis; M O Leach
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.